Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

Journal Browser

Molecular Diagnosis and Treatments of Diabetes Mellitus

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Benefits of Publishing in a Special Issue
Published Papers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (20 January 2025) | Viewed by 8821

Share This Special Issue

Special Issue Editor

Dr. Mihail Virgil Boldeanu

E-Mail Website
Guest Editor

Department of Immunology, University of Medicine and Pharmacy, 200349 Craiova, Romania
Interests: pancreatic disorders; polymorphism; genotype; VEGFR-2; vitamin C; ascorbic acid; diabetes mellitus; periodontal disease; antigens; monoclonal antibody; NLRP3; citokines; pro-angiogenic factors; chronic periodontitis; case-control; matrix metalloproteinase; periodontal parameters
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In recent years, several studies conducted among different populations, as well as on mice, have revealed new knowledge about the role of neurotransmission and inflammation in type 2 diabetes mellitus (T2DM) that is not currently included in protocols.

Thus, a more solid functional link between these neurotransmitters and markers of inflammation must be established. To better understand and describe this complex association, further large-scale studies among different patient groups are needed.

Epidemiological studies have established an association between inflammatory molecular biomarkers and the occurrence of T2DM and its complications. Because fat cells, macrophages, and other immune cells in the expanding adipose tissue interact with each other, it seems that adipose tissue is a major source of these molecular biomarkers. The identification of key molecular triggers of inflammation in T2DM is still poorly understood. The inflammatory response probably plays a part in the development of T2DM by making insulin less effective. This is made worse when hyperglycemia is present, which makes diabetes complications worse over time. Targeting inflammatory molecular pathways could be a component of strategies to prevent and control diabetes and its associated complications.

Serotonin, released by intestinal enterochromaffin cells, appears to regulate energy homeostasis through peripheral mechanisms. Serotonergic effects on energy balance leads to secondary effects on glucose homeostasis, based on a well-established link between obesity and insulin resistance.

This Special Issue invites research papers to highlight the involved DM molecular markers and pathways and outline perspectives for personalized DM diagnosis and treatment. Systemizing reviews on these topics are also warmly welcome.

Dr. Mihail Virgil Boldeanu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

metabolic disorders
diabetes mellitus
inflammation
neurotransmitter
inflammatory biomarkers
molecular target
molecular diagnostics
therapeutics
insulin resistance

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (6 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2518 KiB

Open AccessArticle

Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial

by Rosaura Casas, Andrea Tompa, Karin Åkesson, Pedro F. Teixeira, Anton Lindqvist and Johnny Ludvigsson

Int. J. Mol. Sci. 2025, 26(1), 374; https://doi.org/10.3390/ijms26010374 - 4 Jan 2025

Viewed by 1215

Abstract

Immunotherapies aimed at preserving residual beta cell function in type 1 diabetes have been successful, although the effect has been limited, or raised safety concerns. Transient effects often observed may necessitate redosing to prolong the effect, although this is not always feasible or safe. Treatment with intralymphatic GAD-alum has been shown to be tolerable and safe in persons with type 1 diabetes and has shown significant efficacy to preserve C-peptide with associated clinical benefit in individuals with the human leukocyte antigen DR3DQ2 haplotype. To further explore the feasibility and advantages of redosing with intralymphatic GAD-alum, six participants who had previously received active treatment with intralymphatic GAD-alum and carried HLA DR3-DQ2 received one additional intralymphatic dose of 4 μg GAD-alum in the pilot trial DIAGNODE-B. The participants also received 2000 U/day vitamin D (Calciferol) supplementation for two months, starting one month prior to the GAD-alum injection. During the 12-month follow-up, residual beta cell function was estimated with Mixed-Meal Tolerance Tests, and clinical and immune responses were observed. C-peptide decreased minimally, and most patients showed stable HbA1c and IDAA1c. The mean % TIR increased while the mean daily insulin dose decreased at month 12 compared to the baseline. Redosing with GAD-alum seems to be safe and tolerable, and may prolong the disease modification elicited by the original GAD-alum treatment. Full article

(This article belongs to the Special Issue Molecular Diagnosis and Treatments of Diabetes Mellitus)

► Show Figures

Figure 1

14 pages, 1279 KiB

Open AccessArticle

Kallistatin as a Potential Marker of Therapeutic Response During Alpha-Lipoic Acid Treatment in Diabetic Patients with Sensorimotor Polyneuropathy

by Marcell Hernyák, László Imre Tóth, Sára Csiha, Ágnes Molnár, Hajnalka Lőrincz, György Paragh, Mariann Harangi and Ferenc Sztanek

Int. J. Mol. Sci. 2024, 25(24), 13276; https://doi.org/10.3390/ijms252413276 - 11 Dec 2024

Viewed by 601

Abstract

Diabetic sensorimotor neuropathy (DSPN) is strongly associated with the extent of cellular oxidative stress and endothelial dysfunction in type 2 diabetes (T2DM). Alpha-lipoic acid (ALA) attenuates the progression of DSPN through its antioxidant and vasculoprotective effects. Kallistatin has antioxidant and anti-inflammatory properties. We aimed to evaluate changes in kallistatin levels and markers of endothelial dysfunction in patients with T2DM and DSPN following six months of treatment with 600 mg/day of ALA. A total of 54 patients with T2DM and DSPN and 24 control patients with T2DM but without neuropathy participated in this study. The serum concentrations of kallistatin, ICAM-1, VCAM-1, oxLDL, VEGF, ADMA, and TNF-alpha were measured by an ELISA. Peripheral sensory neuropathy was assessed with neuropathy symptom questionnaires and determination of the current perception threshold. After ALA treatment, the level of kallistatin significantly decreased, as well as the levels of TNF-alpha and ADMA. Changes in kallistatin levels were positively correlated with changes in oxLDL. The improvement in DSPN symptoms following ALA treatment showed a positive correlation with changes in kallistatin, VEGF, oxLDL, and ADMA levels. Based on our results, kallistatin could represent a potential new biomarker for assessing therapeutic response during ALA treatment in patients with DSPN. Full article

(This article belongs to the Special Issue Molecular Diagnosis and Treatments of Diabetes Mellitus)

► Show Figures

Graphical abstract

17 pages, 1798 KiB

Open AccessArticle

Weight Changes Are Linked to Adipose Tissue Genes in Overweight Women with Polycystic Ovary Syndrome

by Anton Hellberg, Daniel Salamon, Dorina Ujvari, Mikael Rydén and Angelica Lindén Hirschberg

Int. J. Mol. Sci. 2024, 25(21), 11566; https://doi.org/10.3390/ijms252111566 - 28 Oct 2024

Viewed by 1064

Abstract

Women with polycystic ovary syndrome (PCOS) have varying difficulties in achieving weight loss by lifestyle intervention, which may depend on adipose tissue metabolism. The objective was to study baseline subcutaneous adipose tissue gene expression as a prediction of weight loss by lifestyle intervention in obese/overweight women with PCOS. This is a secondary analysis of a randomized controlled trial where women with PCOS, aged 18–40 and body mass index (BMI) ≥ 27 were initially randomized to either a 4-month behavioral modification program or minimal intervention according to standard care. Baseline subcutaneous adipose tissue gene expression was related to weight change after the lifestyle intervention. A total of 55 obese/overweight women provided subcutaneous adipose samples at study entry. Weight loss was significant after behavioral modification (−2.2%, p = 0.0014), while there was no significant weight loss in the control group (−1.1%, p = 0.12). In microarray analysis of adipose samples, expression of 40 genes differed significantly between subgroups of those with the greatest weight loss or weight gain. 10 genes were involved in metabolic pathways including glutathione metabolism, gluconeogenesis, and pyruvate metabolism. Results were confirmed by real-time polymerase chain reaction (RT-PCR) in all 55 subjects. Expressions of GSTM5, ANLN, and H3C2 correlated with weight change (R = −0.41, p = 0.002; R = −0.31, p = 0.023 and R = −0.32, p = 0.016, respectively). GSTM5, involved in glutathione metabolism, was the strongest predictor of weight loss, and together with baseline waist-hip ratio (WHR) explained 31% of the variation in body weight change. This study shows that baseline subcutaneous adipose tissue genes play a role for body weight outcome in response to lifestyle intervention in overweight/obese women with PCOS. Full article

(This article belongs to the Special Issue Molecular Diagnosis and Treatments of Diabetes Mellitus)

► Show Figures

Figure 1

14 pages, 1113 KiB

Open AccessArticle

The 5:2 Diet Affects Markers of Insulin Secretion and Sensitivity in Subjects with and without Type 2 Diabetes—A Non-Randomized Controlled Trial

by Neda Rajamand Ekberg, Anton Hellberg, Michaela Linn Sundqvist, Angelica Lindén Hirschberg, Sergiu-Bogdan Catrina and Kerstin Brismar

Int. J. Mol. Sci. 2024, 25(17), 9731; https://doi.org/10.3390/ijms25179731 - 8 Sep 2024

Cited by 1 | Viewed by 2160

Abstract

This non-randomized controlled trial aimed to compare the effect of the 5:2 diet on insulin levels as a primary outcome and markers of insulin secretion (connecting peptide (C-peptide) and insulin-like growth factor binding protein-1 (IGFBP-1)) and sensitivity (Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)), as well as body composition as secondary outcomes in overweight/obese individuals with and without type 2 diabetes (T2D). Ninety-seven participants (62% women), 35 with T2D and 62 BMI- and waist-matched controls without T2D, followed the 5:2 diet (two days per week of fasting) for six months with a 12-month follow-up. At six months, there was no loss to follow-up in the T2D group, whereas four controls discontinued this study. Overall, 82% attended the 12-month follow-up. After the intervention, insulin levels decreased in the control group and glucose decreased in the T2D group, while C-peptide, HOMA-IR, waist circumference, BMI, trunk, and total fat% decreased in both groups. Furthermore, low IGFBP-1, indicating hyperinsulinemia, improved in the T2D group. The changes in fasting glucose and waist measurement were significantly more improved in the T2D group than in the controls. Persistent positive effects were observed at the 12-month follow-up. The 5:2 diet for six months was feasible and efficient to reduce markers of insulin secretion and resistance and therefore holds promise as management of overweight/obesity in subjects with and without T2D. Full article

(This article belongs to the Special Issue Molecular Diagnosis and Treatments of Diabetes Mellitus)

► Show Figures

Figure 1

13 pages, 5339 KiB

Open AccessArticle

Cilostazol Ameliorates Motor Dysfunction and Schwann Cell Impairment in Streptozotocin-Induced Diabetic Rats

by Lin-Li Chang, Yu-Ming Wu, Hung-Chen Wang, Kuang-Yi Tseng, Yi-Hsuan Wang, Yen-Mou Lu and Kuang-I Cheng

Int. J. Mol. Sci. 2024, 25(14), 7847; https://doi.org/10.3390/ijms25147847 - 18 Jul 2024

Cited by 1 | Viewed by 1290

Abstract

This study investigated the effects of cilostazol on motor dysfunction, spinal motor neuron abnormalities, and schwannopathy in rats with diabetes. Diabetes mellitus (DM) was induced in rats via femoral intravenous streptozotocin (STZ) injection (60 mg/kg). After successful DM induction, cilostazol was administered on day 15 via oral gavage (100 mg/kg/day) for 6 weeks until sacrifice. Behavioral assays, including motor function, were performed weekly. The sciatic nerve, L5 spinal cord, and spinal ventral root were collected to evaluate the expression of the glial fibrillary acidic protein (GFAP), myelin protein zero (P0), and choline acetyltransferase (ChAT) by immunofluorescence and Western blotting. DM rats displayed decreased running speeds, running distances, and toe spread but increased foot pressure. In addition, loss of non-myelinating Schwann cells and myelin sheaths was observed in the sciatic nerve and L5 spinal ventral root. Reduced numbers of motor neurons were also found in the L5 spinal ventral horn. Cilostazol administration significantly potentiated running speed and distance; increased hind paw toe spread; and decreased foot pressure. In the sciatic nerve and L5 spinal ventral root, cilostazol treatment significantly improved non-myelinated Schwann cells and increased myelin mass. ChAT expression in motor neurons in the spinal ventral horn was improved, but not significantly. Cilostazol administration may protect sensorimotor function in diabetic rats. Full article

(This article belongs to the Special Issue Molecular Diagnosis and Treatments of Diabetes Mellitus)

► Show Figures

Figure 1

Review

Jump to: Research

16 pages, 748 KiB

Open AccessReview

Genetic Variants Influence the Development of Diabetic Neuropathy

by Noémi Hajdú, Ramóna Rácz, Dóra Zsuzsanna Tordai, Magdolna Békeffy, Orsolya Erzsébet Vági, Ildikó Istenes, Anna Erzsébet Körei, Peter Kempler and Zsuzsanna Putz

Int. J. Mol. Sci. 2024, 25(12), 6429; https://doi.org/10.3390/ijms25126429 - 11 Jun 2024

Cited by 1 | Viewed by 1508

Abstract

The exact mechanism by which diabetic neuropathy develops is still not fully known, despite our advances in medical knowledge. Progressing neuropathy may occur with a persistently favorable metabolic status in some patients with diabetes mellitus, while, in others, though seldom, a persistently unfavorable metabolic status is not associated with significant neuropathy. This might be significantly due to genetic differences. While recent years have brought compelling progress in the understanding of the pathogenetic background—in particular, accelerated progress is being made in understanding molecular biological mechanisms—some aspects are still not fully understood. A comparatively small amount of information is accessible on this matter; therefore, by summarizing the available data, in this review, we aim to provide a clearer picture of the current state of knowledge, identify gaps in the previous studies, and possibly suggest directions for future studies. This could help in developing more personalized approaches to the prevention and treatment of diabetic neuropathy, while also taking into account individual genetic profiles. Full article

(This article belongs to the Special Issue Molecular Diagnosis and Treatments of Diabetes Mellitus)

► Show Figures

Journal Menu

Journal Browser

Molecular Diagnosis and Treatments of Diabetes Mellitus

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (6 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI